Centessa Pharmaceuticals (CNTA) to Release Earnings on Tuesday

Key Points

• Centessa Pharmaceuticals (NASDAQ:CNTA) is set to announce its Q2 2025 quarterly earnings on August 12th, with analysts expecting a loss of $0.34 per share.
• The company’s stock recently traded at $16.50 with a market cap of $2.20 billion, while insiders sold over $3 million worth of shares within the last three months.
• Currently, the average analyst rating for Centessa Pharmaceuticals is a "Moderate Buy" with a consensus price target of $28.10.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) will likely be posting its Q2 2025 quarterly earnings results before the market opens on Tuesday, August 12th. Analysts expect Centessa Pharmaceuticals to post earnings of ($0.34) per share for the quarter.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last posted its quarterly earnings results on Monday, May 12th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.15. On average, analysts expect Centessa Pharmaceuticals to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Centessa Pharmaceuticals Stock Down 0.9%

Shares of CNTA traded down $0.16 during trading hours on Friday, hitting $17.02. The company had a trading volume of 557,955 shares, compared to its average volume of 1,186,054. The firm has a fifty day moving average price of $14.29 and a 200-day moving average price of $14.47. The company has a debt-to-equity ratio of 0.28, a quick ratio of 14.37 and a current ratio of 14.37. The stock has a market capitalization of $2.27 billion, a price-to-earnings ratio of -9.40 and a beta of 1.48. Centessa Pharmaceuticals has a 52-week low of $9.60 and a 52-week high of $19.09.

Analysts Set New Price Targets

CNTA has been the subject of several recent analyst reports. Wall Street Zen raised Centessa Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Thursday, May 22nd. Chardan Capital reaffirmed a "buy" rating and issued a $30.00 price target on shares of Centessa Pharmaceuticals in a research report on Wednesday, July 30th. Needham & Company LLC started coverage on Centessa Pharmaceuticals in a research report on Wednesday, May 28th. They issued a "buy" rating and a $35.00 target price for the company. Oppenheimer started coverage on Centessa Pharmaceuticals in a research report on Thursday, May 8th. They issued an "outperform" rating and a $6.00 target price for the company. Finally, Truist Financial started coverage on Centessa Pharmaceuticals in a research report on Monday, July 21st. They issued a "buy" rating and a $30.00 target price for the company. One investment analyst has rated the stock with a hold rating and eleven have issued a buy rating to the company's stock. According to MarketBeat, Centessa Pharmaceuticals presently has an average rating of "Moderate Buy" and an average target price of $28.10.

Insider Buying and Selling at Centessa Pharmaceuticals

In other news, Director Arjun Goyal purchased 417,646 shares of the business's stock in a transaction on Friday, May 16th. The stock was acquired at an average cost of $12.73 per share, for a total transaction of $5,316,633.58. Following the purchase, the director directly owned 462,585 shares in the company, valued at $5,888,707.05. This trade represents a 929.36% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Saurabh Saha sold 55,000 shares of the business's stock in a transaction dated Monday, July 21st. The shares were sold at an average price of $15.92, for a total value of $875,600.00. Following the sale, the chief executive officer owned 221,017 shares of the company's stock, valued at approximately $3,518,590.64. This represents a 19.93% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 230,322 shares of company stock worth $3,196,684. 7.09% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in CNTA. Geode Capital Management LLC grew its stake in shares of Centessa Pharmaceuticals by 44.7% during the 2nd quarter. Geode Capital Management LLC now owns 87,435 shares of the company's stock valued at $1,149,000 after acquiring an additional 26,994 shares during the period. Jane Street Group LLC bought a new position in shares of Centessa Pharmaceuticals during the 1st quarter valued at approximately $2,176,000. Finally, Millennium Management LLC grew its stake in shares of Centessa Pharmaceuticals by 52.9% during the 1st quarter. Millennium Management LLC now owns 609,188 shares of the company's stock valued at $8,760,000 after acquiring an additional 210,737 shares during the period. 82.01% of the stock is currently owned by institutional investors.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.